Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR Inhibition

PURPOSE: MET amplification is a common resistance mechanism to EGFR inhibition in EGFR-mutant non-small cell lung cancer (NSCLC). Several trials showed encouraging results with combined EGFR and MET inhibition (EGFRi/METi). However, MET amplification has been inconsistently defined and frequently included both polysomy and true amplification. METHODS: This is a multicenter, real-world analysis in patients with disease progression on EGFR inhibition and MET copy number gain (CNG), defined as either true amplification (MET to centromere of chromosome 7 ratio [MET-CEP7]

• Acker, F.
• Klein, A.
• Rasokat, A.
• Eisert, A.
• Kron, A.
• Christopoulos, P.
• Stenzinger, A.
• Kulhavy, J.
• Hummel, H. D.
• Waller, C. F.
• Hummel, A.
• Rittmeyer, A.
• Kropf-Sanchen, C.
• Zimmermann, H.
• Lörsch, A.
• Kauffmann-Guerrero, D.
• Schütz, M.
• Herster, F.
• Thielert, F.
• Demes, M.
• Althoff, F. C.
• Aguinarte, L.
• Heinzen, S.
• Rost, M.
• Schulte, H.
• Stratmann, J.
• Rohde, G.
• Büttner, R.
• Wolf, J.
• Sebastian, M.
• Michels, S.